203 related articles for article (PubMed ID: 23181020)
1. Computational modeling of the metabolic States regulated by the kinase akt.
Mosca E; Alfieri R; Maj C; Bevilacqua A; Canti G; Milanesi L
Front Physiol; 2012; 3():418. PubMed ID: 23181020
[TBL] [Abstract][Full Text] [Related]
2. Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.
Makinoshima H; Takita M; Saruwatari K; Umemura S; Obata Y; Ishii G; Matsumoto S; Sugiyama E; Ochiai A; Abe R; Goto K; Esumi H; Tsuchihara K
J Biol Chem; 2015 Jul; 290(28):17495-504. PubMed ID: 26023239
[TBL] [Abstract][Full Text] [Related]
3. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth.
Sun Q; Chen X; Ma J; Peng H; Wang F; Zha X; Wang Y; Jing Y; Yang H; Chen R; Chang L; Zhang Y; Goto J; Onda H; Chen T; Wang MR; Lu Y; You H; Kwiatkowski D; Zhang H
Proc Natl Acad Sci U S A; 2011 Mar; 108(10):4129-34. PubMed ID: 21325052
[TBL] [Abstract][Full Text] [Related]
4. Metabolic phenotype of bladder cancer.
Massari F; Ciccarese C; Santoni M; Iacovelli R; Mazzucchelli R; Piva F; Scarpelli M; Berardi R; Tortora G; Lopez-Beltran A; Cheng L; Montironi R
Cancer Treat Rev; 2016 Apr; 45():46-57. PubMed ID: 26975021
[TBL] [Abstract][Full Text] [Related]
5. PI3K/AKT/mTOR pathway, hypoxia, and glucose metabolism: Potential targets to overcome radioresistance in small cell lung cancer.
Deng H; Chen Y; Li P; Hang Q; Zhang P; Jin Y; Chen M
Cancer Pathog Ther; 2023 Jan; 1(1):56-66. PubMed ID: 38328610
[TBL] [Abstract][Full Text] [Related]
6. Effects of orexin A on glucose metabolism in human hepatocellular carcinoma in vitro via PI3K/Akt/mTOR-dependent and -independent mechanism.
Liu Y; Zhao Y; Guo L
Mol Cell Endocrinol; 2016 Jan; 420():208-16. PubMed ID: 26549689
[TBL] [Abstract][Full Text] [Related]
7. Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling.
Mediani L; Gibellini F; Bertacchini J; Frasson C; Bosco R; Accordi B; Basso G; Bonora M; Calabrò ML; Mattiolo A; Sgarbi G; Baracca A; Pinton P; Riva G; Rampazzo E; Petrizza L; Prodi L; Milani D; Luppi M; Potenza L; De Pol A; Cocco L; Capitani S; Marmiroli S
Oncotarget; 2016 Feb; 7(5):5521-37. PubMed ID: 26575168
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of miR-214 inhibits proliferation and glycolysis in non-small-cell lung cancer cells via down-regulating the expression of hexokinase 2 and pyruvate kinase isozyme M2.
Zhang K; Zhang M; Jiang H; Liu F; Liu H; Li Y
Biomed Pharmacother; 2018 Sep; 105():545-552. PubMed ID: 29886375
[TBL] [Abstract][Full Text] [Related]
9. Impacts of Oxidative Stress and PI3K/AKT/mTOR on Metabolism and the Future Direction of Investigating Fucoidan-Modulated Metabolism.
Shiau JP; Chuang YT; Cheng YB; Tang JY; Hou MF; Yen CY; Chang HW
Antioxidants (Basel); 2022 May; 11(5):. PubMed ID: 35624775
[TBL] [Abstract][Full Text] [Related]
10. Revving the engine: PKB/AKT as a key regulator of cellular glucose metabolism.
Li X; Hu S; Cai Y; Liu X; Luo J; Wu T
Front Physiol; 2023; 14():1320964. PubMed ID: 38264327
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
Gong T; Cui L; Wang H; Wang H; Han N
J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
[TBL] [Abstract][Full Text] [Related]
12. Proliferating tumor cells mimick glucose metabolism of mature human erythrocytes.
Ghashghaeinia M; Köberle M; Mrowietz U; Bernhardt I
Cell Cycle; 2019 Jun; 18(12):1316-1334. PubMed ID: 31154896
[TBL] [Abstract][Full Text] [Related]
13. Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling.
Grunt TW; Mariani GL
Curr Cancer Drug Targets; 2013 Feb; 13(2):188-204. PubMed ID: 23215720
[TBL] [Abstract][Full Text] [Related]
14. Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction.
Jia L; Huang S; Yin X; Zan Y; Guo Y; Han L
Life Sci; 2018 Sep; 208():123-130. PubMed ID: 30025823
[TBL] [Abstract][Full Text] [Related]
15. Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells.
Bonelli M; Terenziani R; Zoppi S; Fumarola C; La Monica S; Cretella D; Alfieri R; Cavazzoni A; Digiacomo G; Galetti M; Petronini PG
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708306
[No Abstract] [Full Text] [Related]
16. Phosphatase control of 4E-BP1 phosphorylation state is central for glycolytic regulation of retinal protein synthesis.
Gardner TW; Abcouwer SF; Losiewicz MK; Fort PE
Am J Physiol Endocrinol Metab; 2015 Sep; 309(6):E546-56. PubMed ID: 26199279
[TBL] [Abstract][Full Text] [Related]
17. Glycometabolic adaptation mediates the insensitivity of drug-resistant K562/ADM leukaemia cells to adriamycin via the AKT-mTOR/c-Myc signalling pathway.
Zhang X; Ai Z; Chen J; Yi J; Liu Z; Zhao H; Wei H
Mol Med Rep; 2017 Apr; 15(4):1869-1876. PubMed ID: 28259993
[TBL] [Abstract][Full Text] [Related]
18. Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer.
Moench R; Grimmig T; Kannen V; Tripathi S; Faber M; Moll EM; Chandraker A; Lissner R; Germer CT; Waaga-Gasser AM; Gasser M
Oncotarget; 2016 Oct; 7(42):68749-68767. PubMed ID: 27626684
[TBL] [Abstract][Full Text] [Related]
19. Effects of topoisomerase inhibitors that induce DNA damage response on glucose metabolism and PI3K/Akt/mTOR signaling in multiple myeloma cells.
Demel HR; Feuerecker B; Piontek G; Seidl C; Blechert B; Pickhard A; Essler M
Am J Cancer Res; 2015; 5(5):1649-64. PubMed ID: 26175935
[TBL] [Abstract][Full Text] [Related]
20. The sweet trap in tumors: aerobic glycolysis and potential targets for therapy.
Yu L; Chen X; Wang L; Chen S
Oncotarget; 2016 Jun; 7(25):38908-38926. PubMed ID: 26918353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
